跳至主要内容
临床试验/NCT00596791
NCT00596791已完成3 期

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Santen Oy1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Santen Oy
入组人数
150
试验地点
1
主要终点
Change from screening in ocular symptoms and signs

研究概览

简要总结

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

排除标准

  • 未提供

研究组 & 干预措施

1 arm

Other

Open-lable study with one arm.

干预措施: tafluprost (Drug)

结局指标

主要结局

Change from screening in ocular symptoms and signs

时间窗: at week 6 and 12

次要结局

  • Safety and Quality of life parameters.(From Screening (visit 1) to visits at week 2, 6 and 12.)

研究者

发起方
Santen Oy
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验